Summary
Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiovascular and metabolic disease; and hepatic infectious disease. It also offers Alnylam 5x15 program for advancing genetically defined disease targets for the treatment of respiratory syncytial virus and liver cancer. Alnylam employs lipid nanoparticles for intravenous systemic delivery of sRNAi to right body organs and cells so that it could trigger the RNAi mechanism. The company works in partnership with Merck, Medtronic, Roche, Novartis, Biogen, Takeda, Cubist, GlaxoSmithKline, Ascletis, The Medicines Company, Kyowa Hakko Kirin, Monsanto, and Sanofi Genzyme for advancing its RNAi therapeutics. Alnylam is headquartered in Cambridge, Massachusetts, the US.
Alnylam Pharmaceuticals Inc (ALNY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Invitae Enters into Agreement with Alnylam Pharma 13
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 13
BioXcel Enters into Agreement with Alnylam Pharma 14
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 15
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 16
Alnylam Pharma Enters Into Agreement With Genzyme To Develop and Commercialize RNAi Therapeutics 17
Molecular Templates Enters Into Research Collaboration With Alnylam Pharma 19
Precision NanoSystems Enters Into Delivery Collaboration With Alnylam 19
AlCana Extends Co-Development Agreement With UBC And Alnylam 20
Licensing Agreements 21
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 21
Alnylam Pharma Enters into Licensing Agreement with Isis Pharma 23
Isis Pharma Enters into Licensing Agreement with Alnylam Pharma 24
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 25
Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 26
Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 28
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 29
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 30
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 31
Alnylam Pharma Enters Into Licensing Agreement With GlaxoSmithKline 32
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 32
Equity Offering 33
Alnylam Pharma Prices Public Offering of Shares for USD359.4 Million 33
Alnylam Pharma Prices Public Offering of Shares for USD518 Million 35
Alnylam Pharma to Raise USD70.7 Million in Private Placement of Shares 36
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 38
Alnylam Pharma Completes Private Placement Of Shares For US$185 Million 39
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 40
Acquisition 42
Alnylam Pharma Completes Acquisition Of Sirna Therapeutics From Merck 42
Alnylam Pharmaceuticals Inc - Key Competitors 44
Key Employees 45
Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Strategy And Business Planning 48
Sep 20, 2016: Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK 48
Jan 11, 2016: Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline 49
Financial Announcements 51
May 05, 2017: Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity 51
Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 53
Nov 02, 2016: Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity 56
Aug 04, 2016: Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress 59
May 02, 2016: Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress 62
Feb 11, 2016: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress 65
Corporate Communications 69
May 09, 2017: Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders 69
Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 71
Sep 19, 2016: Alnylam Expands and Strengthens Management Team as it Plans for Commercialization 72
Legal and Regulatory 73
Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 73
Product News 74
Jun 11, 2016: Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/2 Study 74
Jun 03, 2016: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data 76
Clinical Trials 77
Feb 02, 2017: Alnylam Presents New Data on Fitusiran at EAHAD 77
Dec 04, 2016: Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors 79
Dec 04, 2016: Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors 81
Dec 03, 2016: Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias 83
Nov 03, 2016: Alnylam to Present New Clinical Results of Fitusiran at 58th Annual Meeting of the American Society of Hematology 85
Nov 03, 2016: Alnylam to Present Phase 1 Results of ALN-AS1 at 58th Annual Meeting of the American Society of Hematology 86
Oct 10, 2016: Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) 87
Sep 07, 2016: Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias 88
Jul 25, 2016: Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders 90
Jul 25, 2016: Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia 2016 World Congress 92
Jul 01, 2016: Alnylam Reports New Results on patisiran at the XV International Symposium on Amyloidosis 93
Jun 27, 2016: Alnylam to Report New Patisiran Results at the XV International Symposium on Amyloidosis 95
Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) 96
Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) 98
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99
List of Tables
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Alnylam Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Invitae Enters into Agreement with Alnylam Pharma 13
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 13
BioXcel Enters into Agreement with Alnylam Pharma 14
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 15
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 16
Alnylam Pharma Enters Into Agreement With Genzyme To Develop and Commercialize RNAi Therapeutics 17
Molecular Templates Enters Into Research Collaboration With Alnylam Pharma 19
Precision NanoSystems Enters Into Delivery Collaboration With Alnylam 19
AlCana Extends Co-Development Agreement With UBC And Alnylam 20
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 21
Alnylam Pharma Enters into Licensing Agreement with Isis Pharma 23
Isis Pharma Enters into Licensing Agreement with Alnylam Pharma 24
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 25
Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 26
Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 28
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 29
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 30
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 31
Alnylam Pharma Enters Into Licensing Agreement With GlaxoSmithKline 32
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 32
Alnylam Pharma Prices Public Offering of Shares for USD359.4 Million 33
Alnylam Pharma Prices Public Offering of Shares for USD518 Million 35
Alnylam Pharma to Raise USD70.7 Million in Private Placement of Shares 36
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 38
Alnylam Pharma Completes Private Placement Of Shares For US$185 Million 39
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 40
Alnylam Pharma Completes Acquisition Of Sirna Therapeutics From Merck 42
Alnylam Pharmaceuticals Inc, Key Competitors 44
Alnylam Pharmaceuticals Inc, Key Employees 45
Alnylam Pharmaceuticals Inc, Subsidiaries 47
List of Figures
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
